Valuation: Damora Therapeutics, Inc.

Market Cap 2.03B 1.78B 1.65B 1.51B 2.85B 196B 2.9B 19.67B 7.71B 95.81B 7.63B 7.46B 330B P/E 2026 *
-17.3x
P/E 2027 * -15.9x
Enterprise Value 1.59B 1.39B 1.29B 1.18B 2.23B 153B 2.27B 15.38B 6.03B 74.92B 5.96B 5.83B 258B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.38%
Yield 2026 *
-
Yield 2027 * -
1 day+4.80%
1 week+17.82%
Current month+26.84%
1 month+55.39%
3 months+24.82%
6 months+18.14%
Current year+43.37%
1 week 29.52
Extreme 29.52
34.89
1 month 21.51
Extreme 21.51
34.89
Current year 16.5
Extreme 16.5001
34.89
1 year 2.45
Extreme 2.45
38.33
3 years 2.01
Extreme 2.01
92.5
5 years 2.01
Extreme 2.01
118.75
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 30/03/2026
Director of Finance/CFO - 01/05/2026
Chief Tech/Sci/R&D Officer 60 05/01/2026
Director TitleAgeSince
Chairman 40 23/03/2026
Director/Board Member 42 10/11/2025
Director/Board Member 41 10/11/2025
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Sell

General Counsel

-245 0.0004%
01/05/26 Other

Chief Financial Officer

312,535 0.5077%
30/03/26 Free

Chief Executive Officer

2,000,000 3.3200%
Change 5-day change 1-year change 3-year change Capi.($)
+4.80%+17.82%+819.79%-44.32% 1.94B
+0.21%-0.79%+53.17%+57.39% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-1.94%+4.35%+402.68% 23.48B
+0.74%+2.32%-16.23%-14.44% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-0.70%-0.91%+24.87%+179.47% 14.06B
Average +1.34%-1.16%+119.41%+157.56% 23.55B
Weighted average by Cap. +1.50%-2.24%+47.87%+137.98%

Financials

2026 *2027 *
Net sales - -
Net income -117M -102M -94.59M -87M -164M -11.26B -167M -1.13B -443M -5.51B -438M -429M -18.98B -144M -127M -117M -108M -203M -13.92B -206M -1.4B -548M -6.81B -542M -530M -23.46B
Net Debt -443M -388M -359M -330M -623M -42.7B -633M -4.29B -1.68B -20.89B -1.66B -1.63B -71.98B -326M -286M -264M -243M -459M -31.48B -466M -3.16B -1.24B -15.4B -1.23B -1.2B -53.06B
Logo Damora Therapeutics, Inc.
Damora Therapeutics Inc, formerly Galecto, Inc, is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. It offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.
Employees
7
Date Price Change Volume
20/07/26 $32.99 +4.80% 350,606
17/07/26 $31.48 +4.10% 489,023
16/07/26 $30.24 -2.29% 356,045
15/07/26 $30.95 -0.13% 622,554
14/07/26 $30.99 +10.68% 528,478
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
32.99USD
Average target price
43.38USD
Spread / Average Target
+31.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMRA Stock